Outcome of the Analyst/Investors Meet.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals held analyst and investor meetings on 25th March 2026 via Zoom, with 38 participants including institutional investors, boutique funds, and high-net-worth individuals, all slotted into a single 40-minute window (12:00–12:40 PM). The management interacted with attendees and gave an overview of the company's business operations, industry outlook, and growth strategy. The filing confirms that discussions were limited to information already in the public domain and that no unpublished price sensitive information (UPSI) was shared. The disclosure is filed under SEBI's Listing Regulations, and signed by Managing Director Fredun Nariman Medhora.
This is a routine regulatory disclosure and not materially price-sensitive. The high number of participants suggests decent investor interest in the stock, but since no new information was shared, there is no immediate catalyst for a price move. Shareholders should await the company's next earnings update or any new intimation for actionable developments.